Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Gross Profit Margin Ratio?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Gross Profit Margin Ratio is 
3.62 (1Y -0.92% )

ALXN Stock Price & Gross Profit Margin Ratio

Gross Profit Margin Ratio for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Gross Profit Margin Ratio

chevron_right 2021 0.9 -0.4x
( -1.6% / year avg)
chevron_left 1995 1.4
vertical_align_top Peak 3.83 -
vertical_align_bottom Bottom 0.0
arrow_drop_up # Up Years 10 10 of 27
years up.
arrow_drop_down # Down Years 10
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -112.5x faster than it's gross profit margin ratio over the same period.
  • If ALXN shrinks it's stock at the same rate as it's gross profit margin ratio (-1.6%/year) , it's stock price will shrink +85.1% and hit $92.53 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 10 years (0%) it's gross profit margin ratio were also up.
  • ALXN Historical Gross Profit Margin Ratio Table

    Year Gross Profit Margin Ratio YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 0.9 -75.2% - -
    4/1/2020 3.65 -0.9% - -
    4/1/2019 3.68 3.3% - -
    4/1/2018 3.56 -0.0% - -
    4/1/2017 3.56 29.5% - -
    4/1/2016 2.75 -24.3% - -
    4/1/2015 3.64 -0.4% - -
    4/1/2014 3.65 -1.9% - -
    4/1/2013 3.72 5.5% - -
    4/1/2012 3.53 0.2% - -
    4/1/2011 3.52 -0.4% - -
    4/1/2010 3.54 -0.6% - -
    4/1/2009 3.56 0.5% - -
    4/1/2008 3.54 8.3% - -
    4/1/2007 3.27 227.3% - -
    4/1/2006 1.0 - - -
    4/1/2005 0.0 - - -
    4/1/2004 0.0 - - -
    4/1/2003 0.0 - - -
    4/1/2002 0.0 - - -
    4/1/2001 0.0 - - -
    4/1/2000 0.0 - - -
    4/1/1999 0.0 - - -
    4/1/1998 0.0 -100.0% - -
    4/1/1997 2.5 -34.8% - -
    4/1/1996 3.83 173.8% - -
    4/1/1995 1.4 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Gross profit margin is a profitability ratio that calculates the percentage of sales that exceed the cost of goods sold. In other words, it measures how efficiently a company uses its materials and labor to produce and sell products profitably. You can think of it as the amount of money from product sales left over after all of the direct costs associated with manufacturing the product have been paid. These direct costs are typically called cost of goods sold or COGS and usually consist of raw materials and direct labor.

    For more detailed definitions, please see Investopedia.